MLYS vs ATRO Comparison

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Astronics Corporation is a provider of technologies to the aerospace, defense, and electronics industries, offering high-performance electrical power generation and distribution systems, motion systems, lighting and safety systems, avionics products, systems certification, aircraft structures, and automated test systems. The company operates through two reportable segments, Aerospace and Test Systems. The Aerospace segment designs and manufactures products for the aerospace and defense industry and generates the majority of revenue, while the Test Systems segment designs, develops, manufactures, and maintains automated test systems for the aerospace and defense, communications, and mass transit industries. The company derives the majority of its revenue from the United States.